Overview
CJC-1295 (also referenced as CJC1295, cjc-1295 peptide, or Modified GRF 1-29) is a synthetic analog of growth hormone-releasing hormone (GHRH), the endogenous hypothalamic peptide that stimulates the anterior pituitary gland to secrete growth hormone (GH). Developed by ConjuChem Biotechnologies, CJC-1295 is a tetrasubstituted 30-amino-acid peptide based on the first 29 amino acids of native GHRH, with four amino acid substitutions that confer significantly enhanced metabolic stability and receptor binding affinity. The compound is available in two primary forms: CJC-1295 without DAC (Modified GRF 1-29), which has a half-life of approximately 30 minutes and produces pulsatile GH release; and CJC-1295 with DAC (Drug Affinity Complex), which covalently binds to serum albumin to extend the half-life to 5.8–8.1 days.
Mechanism of Action
CJC-1295 acts as a functional agonist at the GHRH receptor (GHRHR), a G-protein coupled receptor expressed on the surface of pituitary somatotroph cells. Upon binding, CJC-1295 activates adenylyl cyclase via the Gαs protein, increasing intracellular cyclic AMP (cAMP) concentrations. Elevated cAMP activates protein kinase A (PKA), which phosphorylates downstream targets that ultimately trigger the synthesis and secretion of growth hormone from somatotroph secretory granules. The secreted growth hormone then acts on the liver and peripheral tissues to stimulate the production of insulin-like growth factor-1 (IGF-1), the primary mediator of GH's anabolic and tissue-repair effects. In a landmar
Research Evidence
- 2–10 fold increase in mean GH concentrations in healthy adult subjects (Teichman et al., 2006)
- 1.5–3 fold increase in IGF-1 levels persisting up to 28 days after multiple doses
- Preserves physiological pulsatility of GH secretion (Ionescu & Frohman, 2006)
- Estimated half-life of 5.8–8.1 days (DAC form) vs. ~30 min (without DAC)
- Normalizes growth in GHRH-knockout mouse models (Alba et al., 2006)
Bottom line: CJC-1295 is one of the most clinically studied GHRH analogs, with published human pharmacokinetic data. The DAC (Drug Affinity Complex) version binds to albumin in the blood, extending its half-life from 30 minutes to nearly a week. It is a research-only compound classified as prohibited by WADA.
Research Protocols & Dosage
Evidence-based research protocols, administration routes, and dosage considerations for CJC-1295 are detailed in the full compound profile. See also: Dosage guide for CJC-1295.
Sourcing & Quality
CJC-1295 is available from Purgo Labs with third-party COA verification and research-grade purity standards. View CJC-1295 at Purgo Labs.